Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$17.49
−$0.05 · -0.29%
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Previous close
$17.49
−$0.05 · -0.29%
After-hours
$17.51
+$0.02 · +0.11%
Oct 7, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Day range
Current $17.49
52-week range
Current $17.49
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
72
Undervalued
Sentiment
60
Mixed
Risk
24
Moderate Risk
Momentum
59
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Day range
Current $17.49
52-week range
Current $17.49
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 14.3B USD | 14.74B USD | 15.43B USD | 16.26B USD | 17.89B USD |
| Cost of goods sold | 9.29B USD | 9.12B USD | 8.99B USD | 9.77B USD | 12.31B USD |
| Gross profit | 5.01B USD | 5.62B USD | 6.44B USD | 6.5B USD | 5.58B USD |
| Research and development | 965.9M USD | 808.7M USD | 805.2M USD | 662.2M USD | 681M USD |
| Selling, general, and administrative | 3.79B USD | 4.43B USD | 4.65B USD | 4.18B USD | 4.53B USD |
| Operating expenses | 7.68B USD | 5.61B USD | 5.67B USD | 4.88B USD | 5.61B USD |
| Interest expense | 471.3M USD | 550M USD | 573.1M USD | 592.4M USD | 636.2M USD |
| Depreciation and amortization | 2.8B USD | 2.71B USD | 2.74B USD | 3.03B USD | 4.51B USD |
| Operating income | −2.66B USD | 10.1M USD | 766.2M USD | 1.61B USD | −34M USD |
| Net income | −3.51B USD | −634.2M USD | 54.7M USD | 2.08B USD | −1.27B USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$22.17
26.76% upsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P 500 ETF1557.T38.74B0.03%129.41T JPY0.09%¥122,700-0.57%
Vanguard Morningstar Total Stock Market ETFVTI611.9M0.03%2.3T USD0.03%$381.03-0.40%
Vanguard S&P 500 ETFVOO510.87M0.03%1.8T USD0.03%$714.34-0.26%
Vanguard Morningstar Small-Cap ETFVB442.34M0.24%185.3B USD0.03%$286.98-1.41%
Vanguard Morningstar Small-Cap Value ETFVBR280.95M0.41%68.2B USD0.05%$232.17-1.32%
iShares Core S&P 500 ETFIVV268.41M0.03%899.63B USD0.03%$780.58-0.25%
State Street SPDR S&P 500 ETFSPY244.63M0.03%819.04B USD0.09%$777.22-0.24%
Invesco S&P 500 Equal Weight ETFRSP206.7M0.21%96.47B USD0.20%$210.6-0.81%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Value ETFVBRiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYInvesco S&P 500 Equal Weight ETFRSPAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
